Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • EP full-text search
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Technology insight reports
    • Data
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Technology platforms
      • Overview
      • Plastics in transition
      • Water innovation
      • Space innovation
      • Technologies combatting cancer
      • Firefighting technologies
      • Clean energy technologies
      • Fighting coronavirus
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
    Image
    Plastics in Transition

    Technology insight report on plastic waste management

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • Find a professional representative
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • File with us
      • Interact with us on your files
      • Online Filing & fee payment outages
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Find out how the Unitary Patent can enhance your IP strategy

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • Guidelines
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National measures relating to the Unitary Patent
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
    Image
    Law and practice scales 720x237

    Keep up with key aspects of selected BoA decisions with our monthly "Abstracts of decisions”

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • European Inventor Network
      • The 2024 event
    • Young Inventors Prize
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
      • The 2025 event
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Water-related technologies
      • CodeFest
      • Green tech in focus
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    From ideas to inventions: tune into our podcast for the latest in tech and IP

  • Learning

    Learning

    The European Patent Academy – the point of access to your learning

    Go to overview 

    • Overview
    • Learning activities and paths
      • Overview
      • Learning activities
      • Learning paths
    • EQE and EPAC
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Overview
      • Business and IP managers
      • EQE and EPAC Candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)
    Image
    Patent Academy catalogue

    Have a look at the extensive range of learning opportunities in the European Patent Academy training catalogue

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • Official celebrations
      • Member states’ video statements
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Overview
      • Communiqués
      • Calendar
      • Documents and publications
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Sustainability at the EPO
      • Overview
      • Environmental
      • Social
      • Governance and Financial sustainability
    • Services & activities
      • Overview
      • Our services & structure
      • Quality
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Overview
      • Technologies
      • Innovation actors
      • Policy and funding
      • Tools
      • About the Observatory
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Sustainable Procurement Policy
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
      • "Long Night"
    Image
    Patent Index 2024 keyvisual showing brightly lit up data chip, tinted in purple, bright blue

    Track the latest tech trends with our Patent Index

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
    • Go back
    • New to patents
  • New to patents
    • Go back
    • Your business and patents
    • Why do we have patents?
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Is it patentable?
    • Are you first?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Release notes
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • EP full-text search
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Technology insight reports
    • Data
      • Go back
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
        • Boards of Appeal decisions
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server web service
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Technology platforms
      • Go back
      • Overview
      • Plastics in transition
        • Go back
        • Overview
        • Plastics waste recovery
        • Plastics waste recycling
        • Alternative plastics
      • Innovation in water technologies
        • Go back
        • Overview
        • Clean water
        • Protection from water
      • Space innovation
        • Go back
        • Overview
        • Cosmonautics
        • Space observation
      • Technologies combatting cancer
        • Go back
        • Overview
        • Prevention and early detection
        • Diagnostics
        • Therapies
        • Wellbeing and aftercare
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
    • Helpful resources
      • Go back
      • Overview
      • First time here?
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
          • Introductory brochures
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Exchange data with us using an API
          • Go back
          • Release notes
      • Get access
        • Go back
        • Overview
        • Release notes
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact with us on your files
        • Go back
        • Release notes
      • Online Filing & fee payment outages
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Overview
      • Request for examination
    • Find a professional representative
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • Guidelines
        • Go back
        • Overview
        • EPC Guidelines
        • PCT-EPO Guidelines
        • Unitary Patent Guidelines
        • Guidelines revision cycle
        • Consultation results
        • Summary of user responses
        • Archive
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
        • Go back
        • Travaux préparatoires to UP and UPC
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • About the award
      • Categories and prizes
      • Meet the inventors
      • Nominations
      • European Inventor Network
        • Go back
        • 2024 activities
        • 2025 activities
        • Rules and criteria
        • FAQ
      • The 2024 event
    • Young Inventors Prize
      • Go back
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
      • The 2025 event
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Water-related technologies
      • CodeFest
        • Go back
        • CodeFest Spring 2025 on classifying patent data for sustainable development
        • Overview
        • CodeFest 2024 on generative AI
        • CodeFest 2023 on Green Plastics
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • Learning activities and paths
      • Go back
      • Overview
      • Learning activities: types and formats
      • Learning paths
    • EQE and EPAC
      • Go back
      • Overview
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Compendium
          • Go back
          • Overview
          • Paper F
          • Paper A
          • Paper B
          • Paper C
          • Paper D
          • Pre-examination
        • Candidates successful in the European qualifying examination
        • Archive
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventor's handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
          • Competition and market potential
          • Assessing the risk ahead
          • Proving the invention
          • Protecting your idea
          • Building a team and seeking funding
          • Business planning
          • Finding and approaching companies
          • Dealing with companies
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • Business decision-makers
          • IP professionals
          • Stakeholders of the Innovation Ecosystem
      • EQE and EPAC Candidates
        • Go back
        • Overview
        • Paper F brain-teasers
        • Daily D questions
        • European qualifying examination - Guide for preparation
        • EPAC
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Modular IP Education Framework (MIPEF)
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
        • PATLIB Knowledge Transfer to Africa
          • Go back
          • Core activities
          • Stories and insights
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Official celebrations
      • Overview
      • Member states’ video statements
        • Go back
        • Albania
        • Austria
        • Belgium
        • Bulgaria
        • Croatia
        • Cyprus
        • Czech Republic
        • Denmark
        • Estonia
        • Finland
        • France
        • Germany
        • Greece
        • Hungary
        • Iceland
        • Ireland
        • Italy
        • Latvia
        • Liechtenstein
        • Lithuania
        • Luxembourg
        • Malta
        • Monaco
        • Montenegro
        • Netherlands
        • North Macedonia
        • Norway
        • Poland
        • Portugal
        • Romania
        • San Marino
        • Serbia
        • Slovakia
        • Slovenia
        • Spain
        • Sweden
        • Switzerland
        • Türkiye
        • United Kingdom
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Go back
      • Overview
      • Communiqués
        • Go back
        • 2024
        • Overview
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
        • Go back
        • Driver 1: People
        • Driver 2: Technologies
        • Driver 3: High-quality, timely products and services
        • Driver 4: Partnerships
        • Driver 5: Financial sustainability
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Sustainability at the EPO
      • Go back
      • Overview
      • Environmental
        • Go back
        • Overview
        • Inspiring environmental inventions
      • Social
        • Go back
        • Overview
        • Inspiring social inventions
      • Governance and Financial sustainability
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Dynamic Purchasing System (DPS) publications
      • Sustainable Procurement Policy
      • About eTendering
      • Invoicing
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Quality Action Plan
        • Quality dashboard
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
        • Integrated management at the EPO
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
        • Surveys
          • Go back
          • Overview
          • Detailed methodology
          • Search services
          • Examination services, final actions and publication
          • Opposition services
          • Formalities services
          • Customer services
          • Filing services
          • Key Account Management (KAM)
          • Website
          • Archive
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Go back
      • Overview
      • Technologies
        • Go back
        • Overview
        • Innovation against cancer
        • Assistive robotics
        • Space technologies
      • Innovation actors
        • Go back
        • Overview
        • Startups and SMEs
          • Go back
          • Overview
          • Publications
        • Research universities and public research organisations
      • Policy and funding
        • Go back
        • Overview
        • Financing innovation programme
          • Go back
          • Overview
          • Our studies on the financing of innovation
          • EPO initiatives for patent applicants
          • Financial support for innovators in Europe
        • Patents and standards
          • Go back
          • Overview
          • Publications
          • Patent standards explorer
      • Tools
        • Go back
        • Overview
        • Deep Tech Finder
      • About the Observatory
        • Go back
        • Overview
        • Work plan
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2023
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • 50 years of the EPC
          • Strategic key performance indicators
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
        • Go back
        • Insight into computer technology and AI
        • Insight into clean energy technologies
        • Statistics and indicators
          • Go back
          • European patent applications
            • Go back
            • Key trend
            • Origin
            • Top 10 technical fields
              • Go back
              • Computer technology
              • Electrical machinery, apparatus, energy
              • Digital communication
              • Medical technology
              • Transport
              • Measurement
              • Biotechnology
              • Pharmaceuticals
              • Other special machines
              • Organic fine chemistry
            • All technical fields
          • Applicants
            • Go back
            • Top 50
            • Categories
            • Women inventors
          • Granted patents
            • Go back
            • Key trend
            • Origin
            • Designations
      • Data to download
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Go back
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
        • Go back
        • Catalyst lab & Deep vision
          • Go back
          • Irene Sauter (DE)
          • AVPD (DK)
          • Jan Robert Leegte (NL)
          • Jānis Dzirnieks (LV) #1
          • Jānis Dzirnieks (LV) #2
          • Péter Szalay (HU)
          • Thomas Feuerstein (AT)
          • Tom Burr (US)
          • Wolfgang Tillmans (DE)
          • TerraPort
          • Unfinished Sculpture - Captives #1
          • Deep vision – immersive exhibition
          • Previous exhibitions
        • The European Patent Journey
        • Sustaining life. Art in the climate emergency
        • Next generation statements
        • Open storage
        • Cosmic bar
      • "Long Night"
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Information from the Boards of Appeal
    • Procedure
    • Oral proceedings
    • About the Boards of Appeal
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2025
      • Archive
    • Annual list of cases
    • Communications
    • Annual reports
      • Go back
      • Overview
    • Publications
      • Go back
      • Abstracts of decisions
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Patent Knowledge Products and Services
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Glossary
    • RSS feeds
Board of Appeals
Decisions

Recent decisions

Overview
  • 2025 decisions
  • 2024 decisions
  • 2023 decisions
  1. Home
  2. T 2197/10 (APRIL Receptor/BIOGEN) 17-09-2015
Facebook X Linkedin Email

T 2197/10 (APRIL Receptor/BIOGEN) 17-09-2015

European Case Law Identifier
ECLI:EP:BA:2015:T219710.20150917
Date of decision
17 September 2015
Case number
T 2197/10
Petition for review of
-
Application number
00968780.7
IPC class
A61K 38/17
Language of proceedings
EN
Distribution
NO DISTRIBUTION (D)

Download and more information:

Decision in EN 481 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

APRIL Receptor (BCMA) and uses thereof

Applicant name

Biogen Idec MA Inc.

Apotech R&D S.A.

Opponent name
Amgen Inc.
Board
3.3.04
Headnote
-
Relevant legal provisions
European Patent Convention Art 56
Rules of procedure of the Boards of Appeal Art 13(1)
Keywords
All requests: Inventive step (no)
Catchword
-
Cited decisions
T 0816/90
T 0609/02
R 0016/09
Citing decisions
-

I. Appeals were filed by the two patent proprietors (hereinafter "appellant I") and the opponent (hereinafter "appellant II") against the interlocutory decision of the opposition division maintaining in amended form European patent

No. 1 223 964, entitled "April Receptor (BCMA) And Uses Thereof".

II. The patent had been opposed by appellant II under Article 100(a) EPC, on the grounds of lack of novelty (Article 54 EPC) and lack of inventive step (Article 56 EPC) and under Articles 100(b) and 100(c) EPC.

III. The opposition division decided that the subject-matter of claim 1 of the patent as granted and of the first auxiliary request did not involve an inventive step. Claim 1 of auxiliary request 2 was found not to comply with the requirements of Article 123(3) EPC. Auxiliary request 3 however was found to meet the requirements of the EPC.

IV. In statement of grounds of appeal, appellant I requested as a main request that the patent be maintained as granted. Three auxiliary requests were also filed, corresponding to auxiliary requests 1, 3 and 4 as pending before the opposition division.

V. In a communication dated 27 February 2015, the board informed the parties of its preliminary and non-binding opinion on some of the substantive and legal issues concerning the appeal. In this communication, the question was raised whether a document other than WO 99/12965 (document D3), such as one of the documents mentioned in the description of the patent at paragraphs [0005] to [0008] disclosing methods for treating cancer using receptors binding TNF family ligands, might represent a suitable starting point for the consideration of inventive step in the context of the problem and solution approach.

VI. Both appellants I and II replied to the communication of the board with letters dated 17 July 2015. Appellant I's letter was accompanied by auxiliary claim requests 4 to 7.

VII. Oral proceedings before the board were held on 17 September 2015. During the proceedings, appellant I requested the admission of auxiliary claim requests 8 to 11 into the appeal proceedings. These requests included the definition of the tumour to be treated as a B-cell tumour. At the end of the oral proceedings the Chairwoman announced the decision of the board.

VIII. The following documents are cited in this decision.

D3: WO 99/12965

D5: Madry C. et al., 1998, International

Immunology, 10(11), 1693-1702

D6: Hahne M. et al., 21 September 1998, J. Exp. Med.,

188(6), 1185-1190

D7: Gras M-P. et al., 1995, International Immunology,

7(7), 1093-1106

D11: Rennert P. et al., 4 December 2000, J. Exp. Med.,

192(11), 1677-1683

R1: Aggarwal B. and Natarajan K., 1996, Eur. Cytokine

Netw., 7, 93-124

R2: Beutler B., 1999, J. Rheumatol., 26, 57, 16-21

R3: Browning J.L. et al., 1996, J. Exp. Med., 183(3),

867-878

R4: Mackay F. et al., 1998, Gastroenterology, 115(6),

1464-1475

R5: Gura T., 1997, Science, 277(5327), 768.

IX. Claim 1 of the main request and of auxiliary requests 1 to 7, is reproduced below, with the auxiliary requests having been edited by the board as appropriate:

Main request

"1. Use of

a) a polypeptide comprising an amino acid sequence that is

(i) at least 80% identical to the sequence set forth from amino acid 1 to amino acid 184 of SEQ ID NO:8 and

(ii) capable of binding to APRIL;

b) a polypeptide comprising an amino acid sequence that is

(i) at least 80% identical to the sequence set forth from amino acid 1 to amino acid 52 of SEQ ID NO:8 and

(ii) capable of binding to APRIL;

c) a polypeptide comprising the amino acid sequence set forth from amino acid 8 to amino acid 41 of SEQ ID NO:8; or

d) an antibody directed against SEQ ID NO:8

for the preparation of a pharmaceutical composition for treating a tumour cell that expresses A Proliferation Inducing Ligand (APRIL)."

Auxiliary request 1

1. Use of

[...]

c) an antibody directed against the amino acid sequence set forth from amino acid 1 to amino acid 52 or amino acid 8 to amino acid 41 of SEQ ID NO:8

for the preparation of a pharmaceutical composition for treating a tumour cell that expresses A Proliferation Inducing Ligand (APRIL)."

Auxiliary request 2

"1. Use of

[...]

(b) an antibody directed against the amino acid sequence set forth from amino acid 8 to amino acid 41 of SEQ ID NO: 8

for the preparation of a pharmaceutical composition for treating a tumour cell that expresses A Proliferation Inducing Ligand (APRIL)."

Auxiliary request 3

"1. Use of an antibody directed against the amino acid sequence set forth from amino acid 8 to amino acid 41 of SEQ ID NO:8

for the preparation of a pharmaceutical composition for treating a tumour cell that expresses A Proliferation Inducing Ligand (APRIL)."

Auxiliary request 4

"1. Use of

a) a polypeptide comprising an amino acid sequence that is

(i) at least 80% identical to the sequence set forth from amino acid 1 to amino acid 184 of SEQ ID NO:8

[...]

for the preparation of a pharmaceutical composition for treating a tumour cell that expresses A Proliferation Inducing Ligand (APRIL)."

Auxiliary request 5

"1. Use of

[...]

(c) an antagonistic antibody directed against the amino acid sequence set forth from amino acid 1 to amino acid 52 or amino acid 8 to amino acid 41 of SEQ ID NO:8

for the preparation of a pharmaceutical composition for treating a tumour cell that expresses A Proliferation Inducing Ligand (APRIL)."

Auxiliary request 6

"1. Use of

[...]

(b) an antagonistic antibody directed against the amino acid sequence set forth amino acid 8 to amino acid 41 of SEQ ID NO:8

for the preparation of a pharmaceutical composition for treating a tumour cell that expresses A Proliferation Inducing Ligand (APRIL)."

Auxiliary request 7

"1. Use of an antagonistic antibody directed against the amino acid sequence set forth from amino acid 8 to amino acid 41 of SEQ ID NO:8 for the preparation of a pharmaceutical composition for treating a tumour cell that expresses A Proliferation Inducing Ligand (APRIL)."

X. Appellant I's arguments relevant to the decision can be summarised as follows:

Main request

Inventive step (Article 56 EPC)

Claim 1

The claim related to the medical use of B-cell maturation antigen (BCMA), represented by SEQ ID NO: 8, as well as specific fragments thereof and antibodies recognising it, in the treatment of tumours expressing A Proliferation Inducing Ligand (APRIL).

The contribution to the art made by the invention lay in the identification of BCMA as the receptor for this ligand. While BCMA had been known in the art, its involvement with APRIL had not been known nor had there been any indication of BCMA's utility in the treatment of tumours expressing APRIL. In fact, until the invention represented by the patent, APRIL had been known (from document D3) as an orphan ligand of the TNFalpha family.

Document D3, which disclosed APRIL and its use in treating tumours, was the most suitable starting point for assessing inventive step of the claimed subject-matter. The documents R1 to R5, cited in the description of the patent, provided only general background information relating to members of the TNF superfamily and their receptors. In particular they related to the cytokine TNFalpha (tumour necrosis factor) and its receptor and to the cytokine lymphotoxin alpha/beta and its receptor. These documents did not mention APRIL or relate to the APRIL signalling pathway and could therefore not be considered as the closest prior art for assessing inventive step of the claimed invention.

Starting from document D3 (or document D6, which had the same technical content), the objective technical problem was the provision of alternative pharmaceutical compositions to treat tumours expressing APRIL. In essence, this problem was the identification of a receptor for APRIL to be used for treating APRIL expressing tumours.

This problem was solved by the APRIL receptor (BCMA) and antibodies thereto. BCMA could serve as decoy receptor for APRIL and antibodies to APRIL could block the APRIL/APRIL-R (BCMA) interaction. This solution was not foreseeable from the prior art for a number of reasons.

Firstly, APRIL had been an orphan ligand which in principle had no obvious medical use. Secondly, it would not have been obvious for the skilled person to provide BCMA (and antibodies thereto) as a solution to the technical problem. Starting from document D3, the skilled person would not have had a reasonable expectation of success that BCMA (or antibodies thereto) could or would be a receptor for APRIL. This was because, at the effective date of the patent, the skilled person would not have known that there were in fact three different molecules, BCMA, "transmembrane activator and calcium-modulator and cyclophilin ligand interactor" (TACI) and proteoglycans, which could have been identified as an APRIL receptor.

Moreover, although the identification of a receptor for APRIL might have seemed theoretically straightforward, the skilled person, would have been confronted with unexpected difficulties when following this straightforward path and would have needed to exercise inventive skill to overcome them (cf. decision T 816/90).

In the case of APRIL, the existence of TACI and/or proteoglycans as well as BCMA as receptors for APRIL meant that the skilled person trying to identify such a receptor might have not have arrived at the claimed solution when following the guidance of Example 3 of document D3. Arriving at either TACI or proteoglycans, the skilled person would have had no reason to continue screening for additional receptors.

A further difficulty for the skilled person trying to carry out the scheme proposed in Example 3 of document D3, was that BCMA was not present in all of the cell lines mentioned in document D3. In fact it had later been established that some of these cell lines expressed both TACI and BCMA, some just TACI, some just BCMA and some neither (document D11, Fig. 3). All these uncertainties contributed to the lack of expectation of success.

Auxiliary requests 1 to 7

Inventive step (Article 56 EPC)

Claim 1

The subject-matter of auxiliary requests 1 and 2 related to the medical use of a specific portion of BCMA, namely the extracellular domain (ECD) and antibodies directed to it. Auxiliary request 3 related to the medical use of antibodies binding to the BCMA ECD. There was no pointer in document D3 to the particular extracellular domain fragments or to antibodies thereto, now mentioned in the claim.

Auxiliary requests 4 to 7 corresponded to the main and auxiliary requests 1 to 3 but additionally explicitly defined the antibody as an "antagonistic" antibody. This was done in response to the objection of sufficiency of disclosure and as a precaution in the light of decision T 848/10.

As the subject-matter of the auxiliary requests was progressively further removed from the disclosure of document D3, it required more and more additional and not obvious steps to be carried out by the skilled person to arrive at the claimed subject-matter.

Admissibility of auxiliary requests 8 to 11

These requests had been occasioned by the opinions expressed by the board during the oral proceedings. The amendments were limited and easy to understand, consisting of the further definition of the tumour to be treated as a B-cell tumour. There was no suggestion in document D3 that such a tumour could be treated as claimed. Thus the requests should be admitted into the appeal proceedings.

XI. Appellant II's arguments relevant to the decision can be summarised as follows:

Main request

Inventive step (Article 56 EPC)

Document D3 was the closest prior art for the purpose of assessing inventive step of the subject-matter of claim 1 as it disclosed APRIL and antagonists thereto for anti-cancer applications. It also disclosed the fact that a receptor for APRIL existed but that it had not been identified. From this the skilled person would have understood that the yet to be identified APRIL receptor and antibodies to it were likely to be therapeutically useful for the treatment of tumour cells expressing APRIL (see page 11, lines 11 to 23 of document D3).

In view of this, the technical problem to be solved by the skilled person starting from document D3 was to identify and develop additional methods for treating cancer growth by identifying a receptor for APRIL and generating antibodies thereto. Although document D3 did not provide or characterise an APRIL receptor, it contained repeated suggestions that it would be useful to find and characterise such a protein. In Example 3 it even provided a scheme setting out how the skilled person should go about identifying the receptor and generating antibodies to it. Indeed, document D3 also taught the skilled person which cells a receptor for APRIL was likely to be found in, being those that proliferated in response to APRIL treatment.

Admissibility of the auxiliary requests

Auxiliary requests 1 to 7

There were no objections to the admissibility of auxiliary request 1 to 7.

Auxiliary requests 8 to 11

These requests were filed at the oral proceedings before the board. No convincing reason had been provided for their late submission although the objection of lack of inventive step with respect to document D3, which they were supposed to overcome, had already been raised in the statement of grounds of appeal. The proprietor had therefore had ample time to file the amendments earlier. The late filing meant that there had not been sufficient time to prepare a proper response to them which would now have required an adjournment of the oral proceedings.

Auxiliary request 1 to 7

Inventive step (Article 56 EPC)

Claim 1

Once it was established that the provision of the APRIL receptor itself was obvious, all other subject-matter, such as the use of extra-cellular domain of BCMA or antagonistic antibodies thereto in the treatment of cancer, was suggested directly by document D3.

XII. Appellant I requested that the decision under appeal be set aside and that the patent be maintained as granted (main request) or alternatively, on the basis of one of auxiliary requests 1 to 3, filed with the statement of grounds of appeal or alternatively, on the basis of one of auxiliary requests 4 to 7, filed with letter dated 17 July 2015, or alternatively, on the basis of one of auxiliary requests 8 to 11 filed during the oral proceedings of 17 September 2015.

XIII. Appellant II requested that the decision under appeal be set aside and that the patent be revoked.

Admissibility of the auxiliary requests

Auxiliary requests 1 to 7

1. The admissibility of auxiliary requests 1 to 7 was not contested and the board sees no reason, in view of Article 114(2) EPC in combination with Articles 12(4) and 13(1) RPBA, to either exclude them from (auxiliary requests 1 to 3) or not admit them into (auxiliary requests 4 to 7) the proceedings.

Auxiliary requests 8 to 11

2. These requests were submitted during the oral proceedings before the board.

3. Appellant I argued that the filing of auxiliary requests 8 to 11 during oral proceedings was occasioned by an unexpected procedural development, being the board's opinion on inventive step of the subject-matter of the main request with respect to the disclosure of document D3. The amendments made were limited and easy to understand, consisting only of the addition of the further definition of the tumour to be treated as a B?cell tumour. There was no suggestion in document D3 that a B-cell tumour could be treated as claimed.

4. Appellant II argued that there was no convincing reason provided for the late filing of the requests. The objection of lack of inventive step with respect to document D3 which they were supposed to overcome had already been raised in the statement of grounds of appeal. Moreover, the admission of the auxiliary requests into the appeal proceedings would require a postponement of the oral proceedings to allow sufficient time for them to be properly studied.

5. The admissibility of requests filed after a party has filed its statement setting out the grounds of appeal or the reply thereto and after a board has arranged oral proceedings is subject to Article 13(1) and (3) RPBA. By virtue of Article 13(1) RPBA, a board's discretion in admitting any amendment to a party's case "shall be exercised in view of inter alia the complexity of the new subject-matter submitted, the current state of the proceedings and the need for procedural economy". Thus, the board has discretion to decide which of those criteria take precedence according to the circumstances of the case such that the importance of one of them may outweigh the others (see R 16/09, points 2.2.11 and 2.2.12 of the reasons). Pursuant to Article 13(3) RPBA, amendments shall not be admitted "if they raise issues which the Board or the other party or parties cannot reasonably be expected to deal with without adjournment of the oral proceedings".

6. Claim 1 of each of auxiliary requests 8 to 11 contains the phrase "wherein the tumor cell is a B-cell" in the definition of the medical indication to be treated. This subject-matter has been taken from the description and has presumably not been searched. Thus, admitting these requests into the procedure would have obliged the board to remit the case to the opposition division. Such a course would not be in keeping with considerations of procedural economy.

7. Accordingly, the board has decided that auxiliary requests 8 to 11 are not admitted into the appeal proceedings.

Main request

The claimed invention

8. Claim 1 is, inter alia, for the medical use of a polypeptide comprising the amino acid sequence, SEQ ID NO: 8 (human BCMA), for treating a tumour cell that expresses "A Proliferation Inducing Ligand" (APRIL), where APRIL is a member of the tumour necrosis factor ligand superfamily (see paragraph [0010] of the description).

9. The invention is said to be based on the fact that the inventors "found that BCMA [B-cell mediated protein, also known as B-cell maturation antigen] is a receptor for the tumour necrosis factor, APRIL" (patent in suit, paragraph [0014]).

10. In the patent, BCMA is also referred to as APRIL-receptor (APRIL-R). The amino acid sequence of human full length (184 amino acid) BCMA is given as SEQ ID NO: 8 (paragraph [0018] and Fig. 3B). BCMA (APRIL-R) is said to have an extracellular domain (APRIL-R ECD) which is "a form of APRIL-R which is essentially free of transmembrane and cytoplasmic domains of APRIL-R". The ECD may comprise amino acid residues 1 to 51, 1 to 52, 1 to 53, 4 to 51 or 8 to 41 of SEQ ID NO: 8 (paragraph [0024]). The "transmembrane domain identified for the APRIL-R polypeptide of the present invention is identified pursuant to criteria routinely employed in the art for identifying that type of hydrophobic domain [and] the exact boundaries of a transmembrane domain may vary but most likely by no more than about 5 amino acids at either end of the domain specifically mentioned" (see paragraph [0024] of the patent).

Inventive step (Article 56 EPC)

Closest prior art

11. To assess whether or not a claimed invention meets the requirements of Article 56 EPC, the boards of appeal apply the "problem and solution" approach, which requires as a first step, the identification of the closest prior art. In accordance with the established case law of the boards of appeal, the closest prior art is a teaching in a document conceived for the same purpose or aiming at the same objective as the claimed invention (Case Law of the Boards of Appeal of the European Patent Office, 7th edition 2013, I.D.3.1).

12. The purpose of the present invention is the achievement of the therapeutic effect defined in the claim, i.e. treating a tumour cell that expresses APRIL.

13. Both parties and the opposition division selected document D3 as representing the closest prior art to the claimed subject-matter.

14. Document D3 discloses pharmaceutical compositions comprising the cytokine APRIL for the treatment of cancer (claim 19). It also discloses that "the methods [of the invention] for the treatment of cancers involve the administration to a patient [...] of an effective amount of a claimed composition comprising a blocking agent capable of interfering with the association between APRIL and its receptor. Such blocking agents include, but are not limited to soluble APRIL, anti-APRIL antibodies, anti-APRIL receptor antibodies, or biologically active fragments thereof" (page 26, lines 1 to 10) and that "Pharmaceutical compositions of the invention may comprise a therapeutically effective amount of APRIL, or its receptor [...]" (Id., lines 21 to 23).

15. That the tumour cells to be treated express APRIL is disclosed in document D3 at page 11, lines 20 to 23: "APRIL appears to be unique among the members of the TNF family as it is both abundantly expressed in tumor cells [...]".

16. In summary, document D3 discloses the use of APRIL in the treatment of tumours expressing it and puts forward the hypothesis that the yet unidentified receptor for APRIL and antibodies to it would be able to serve the same purpose.

17. Thus, the purpose of the agents disclosed in document D3 is the same purpose as addressed by the subject-matter of present claim 1.

Technical problem and solution

18. The difference between the closest prior art represented by document D3 and the subject-matter as claimed is that the receptor for APRIL, referred to in a hypothetical way in document D3, is in fact provided and characterised. The technical effect of this difference is the concrete provision of a receptor for APRIL and its use in the treatment of tumours expressing APRIL.

19. Taking into account the closest prior art, the difference between it and the claimed subject-matter and the technical effect of this difference, the objective technical problem can be seen as the provision of a pharmaceutical composition for the treatment of a tumour cell that expresses APRIL (cf. Case Law of the Boards of Appeal of the European Patent Office, 7th edition, II.D. 4.3.1).

20. As to whether the claimed subject-matter provides a solution to the problem, the board observes that the statement of purpose recited in the claim limits its subject-matter to that which provides a solution to the problem (cf. decision T 609/02, point 9 of the reasons).

Obviousness

21. The skilled person starting from the closest prior art document D3 and seeking to solve the problem formulated in point 19.19. would, in the board's view, have been motivated to try to identify the receptor for APRIL. This is because document D3 explicitly suggests that APRIL-R and antibodies to it would be useful in treating cancers expressing APRIL, by blocking the association between a yet to be identified APRIL receptor and this (orphan) ligand.

22. A general protocol for isolation of a receptor binding to APRIL is provided in Example 3 of document D3. The protocol involves the fusion of the 5' end of the extracellular domain of APRIL (i.e. the receptor binding sequence of APRIL) to a marker or tagging sequence and the addition of a leader sequence to force secretion of APRIL in an expression system. According to the Example, "cells expressing the receptor can be identified by exposing them to the tagged ligand. Cells with bound ligand are identified in a FACS experiment by labeling the myc tag with an anti-myc peptide antibody (9E10) followed by phycoerythrin (or a similar label) labeled anti-mouse immunoglobulin. FACS positive cells can be readily identified and would serve as a source of RNA encoding for the receptor. An expression library would then be prepared from this RNA via standard techniques and separated into pools. Pools of clones would be transfected into a suitable host cell and binding of the tagged ligand to receptor positive transfected cells determined via microscopic examination, following labeling of bound myc peptide tag with an enzyme labeled anti-mouse Ig reagent, i.e. galactosidase, alkaline phosphatase or luciferase labeled antibody. Once a positive pool has been identified, the pool size would be reduced until the receptor encoding cDNA is identified. This procedure could be carried out with either the mouse or human APRIL, as one may more readily lead to a receptor".

23. Appellant I argued that the skilled person starting from document D3 would not have had a reasonable expectation of success of at arriving at the claimed solution to the objective technical problem due to the existence of multiple binding partners for APRIL (see Section (X.X. ), paragraphs 6 and 7).

24. The board however, considers that since the knowledge of multiple binding partners for APRIL came to light only after the effective date of the patent (see for instance, document D11) this fact could not have caused the skilled person to be uncertain about the ability of the method disclosed in document D3 (Example 3 - "Isolation of a receptor binding to APRIL") to actually identify BCMA as a receptor for APRIL.

25. It remains to be assessed if the skilled person would when following the above mentioned protocol have arrived at the claimed invention or not.

26. Appellant I argued that the situation was analogous to that dealt with in decision T 816/90 of 7 September 1993, in which the competent board, in point 5.2.7, found that "even when it is possible to theoretically conceive a straightforward approach to solve a specific technical problem, the skilled person might be confronted with unexpected difficulties when trying to put the conceived strategy into practice."

Appellant I's argument was that the existence of multiple receptors for APRIL would have caused the skilled person such unexpected difficulties, because depending on the cell type chosen to "expose to the tagged ligand" (see document D3, page 32, lines 26 and 27) when implementing the protocol of Example 3, any of BCMA, TACI or proteoglycans might have been isolated. Should the skilled person have first obtained TACI, he would not have realised that there was a further receptor and would not have identified BCMA as an APRIL receptor and therefore would not have arrived at the subject-matter of claim 1 without inventive effort.

27. The board considers that in the present case, following the protocol provided in Example 3 of document D3 can be considered to be routine experimental work that could be expected of a skilled person. Furthermore, in the board's judgment, the skilled person, seeking to fill any gaps in the instructions given in Example 3 of document D3 about which cell type to use would, as a matter of normal practice, have turned first to the disclosure of document D3 itself for further instruction. Here he would have found in Example 2 the disclosure of experiments on the induction of proliferation in various tumor cell lines by exposure to purified recombinant FLAG-tagged soluble APRIL. An increase in proliferation being seen in Jurkat T lymphoma cells (page 30, line 31), human Raji B-cell lymphomas, mouse A20 cells (page 31, line 15) and in cell lines of epithelial origin such as COS and HeLa, as well as melanomas (page 31, line 16). The results of the experiment of Example 2 being illustrated in Fig. 3.

28. Thus, document D3 discloses to the skilled person that Jurkat T lymphoma cells, human Raji cell, mouse A20 cells and on cell lines of epithelial origin such as COS and HeLa, as well as melanomas, express a receptor for APRIL and would therefore be good candidate cell lines to use in the protocol Example 3.

29. Post-published document D11 provides evidence that confirms that Raji cells express message for both TACI and BCMA and also are positive for both BAFF and APRIL staining.

30. The board therefore considers that the skilled person, when following the routine methods described in document D3, would have used all of the above mentioned cells lines in the protocol of Example 3 of document D3 and consequently would have isolated both BCMA and TACI, at least from Raji cells.

31. That the (yet to be identified) receptor for APRIL could be useful in treating tumor cells expressing APRIL was explicitly disclosed in document D3 (see page 11, line 24 and page 26, lines 21 and 22)

32. In view of the above considerations, the subject-matter of claim 1 is considered to be obvious in the light of the teaching of document D3. That BCMA is one of several receptors for APRIL does not affect this assessment because it represents one of several equally obvious alternatives.

33. The main request therefore fails to meet the requirements of Article 56 EPC and is not allowable.

Auxiliary request 4

34. This finding also applies to the subject-matter of claim 1 of auxiliary request 4, since it also relates to the medical use of full length BCMA (SEQ ID NO: 8).

Auxiliary requests 1, 2, 3, 5, 6 and 7

Inventive step

35. The medical use for treating a tumour cell that expresses A Proliferation Inducing Ligand (APRIL) of an antagonistic antibody directed to the extracellular domain (ECD) of human BCMA (i.e. "an antibody directed against the amino acid sequence set forth from amino acid 8 to amino acid 41 of SEQ ID NO: 8" that is able to "inhibit receptor ligand interactions";cf. paragraph [0089] of the patent) is common subject-matter of claim 1 of each of auxiliary requests 1 to 3 and 5 to 7.

36. The blocking of the interaction of BCMA with the ligand APRIL using (antagonistic) antibodies to it and the use of such antibodies to treat APRIL expressing tumour cells was explicitly suggested in document D3: "APRIL appears to be unique among the members of the TNF [ligand] family as it is both abundantly expressed in tumor cells and stimulates growth of many different tumor cell lines. Given the apparent role of APRIL is tumorigenesis, the antagonistic antibodies to APRIL, or the APRIL receptor, will provide novel approaches to cancer treatment" (page 11, lines 20 to 25; emphasis added by the board). Since the production of antibodies was routine for the skilled person at the effective date of the patent, the board considers that it would have been a matter of routine for the skilled person to generate antibodies to BCMA. That these antibodies would be able to block (antagonise) its interaction with APRIL was disclosed by document D3. That the antagonistic antibodies should recognise the ECD of BCMA is a consequence of the fact, reflected in its name, that the ECD is exposed on the cell surface and is therefore the part of the molecule involved in ligand interaction and available for antibody binding. Indeed, document D5 disclosed the structural characterisation of BCMA including the identification of the ECD (see page 1696, right column).

37. In view of the above considerations, the board concludes that the subject-matter of claim 1 of auxiliary requests 1 to 3 and 5 to 7 is obvious and therefore lacks an inventive step.

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The patent is revoked.

Footer - Service & support
  • Service & support
    • Website updates
    • Availability of online services
    • FAQ
    • Publications
    • Procedural communications
    • Contact us
    • Subscription centre
    • Official holidays
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
Facebook
European Patent Office
EPO Jobs
Instagram
EuropeanPatentOffice
Linkedin
European Patent Office
EPO Jobs
EPO Procurement
X (formerly Twitter)
EPOorg
EPOjobs
Youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility